The journal Epilepsia will publish a research paper demonstrating the proof of concept of Catalyst Pharmaceutical Partners Inc.’s (Nasdaq: CPRX) CPP-15 in suppressing infantile spasms. The stock price soared 33 cents to $1.93.
Epilepsia To Publish Paper On Catalyst Pharmaceutical’s CPP-15
November 18, 2013 at 04:59 AM EST
